Business Segments · Other (income) expense, net
Innovative Medicine — Other (income) expense, net
Johnson & Johnson Innovative Medicine — Other (income) expense, net increased by 93.8% to -$12.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 92.8%, from -$166.00M to -$12.00M. Over 3 years (FY 2022 to FY 2025), Innovative Medicine — Other (income) expense, net shows a downward trend with a -21.9% CAGR.
Analysis
StatementSegment
CategoryProfitability
SignalContext dependent
VolatilityVolatile
First reportedQ1 2022
Last reportedQ1 2026Apr 22, 2026
Rolls up toOther Income (Expense)
How to read this metric
Large fluctuations can indicate one-time events like legal settlements, asset disposals, or non-core financial gains.
Detailed definition
Includes non-operating items such as interest income, gains or losses on asset sales, and other miscellaneous financial...
Peer comparison
Commonly reported as 'Other Operating Income/Expense' in segment-level financial reporting.
Metric ID:
jnj_segment_innovative_medicine_other_income_expense_netHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $373.50M | $373.50M | $373.50M | $373.50M | $248.25M | $248.25M | $248.25M | $248.25M | -$111.00M | $41.00M | -$155.00M | -$201.00M | -$166.00M | $14.00M | -$368.00M | -$193.00M | -$12.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -33.5% | +0.0% | +0.0% | +0.0% | -144.7% | +136.9% | -478.0% | -29.7% | +17.4% | +108.4% | <-999% | +47.6% | +93.8% |
| YoY Change | — | — | — | — | -33.5% | -33.5% | -33.5% | -33.5% | -144.7% | -83.5% | -162.4% | -181.0% | -49.5% | -65.9% | -137.4% | +4.0% | +92.8% |
Range-$368.00M – $373.50M
CAGR-57.7%
Avg YoY Growth-66.3%
Median YoY Growth-49.5%
Current Streak2 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — other (income) expense, net?
- Johnson & Johnson (JNJ) reported innovative medicine — other (income) expense, net of -$12.00M in Q1 2026.
- How has Johnson & Johnson's innovative medicine — other (income) expense, net changed year-over-year?
- Johnson & Johnson's innovative medicine — other (income) expense, net increased by 92.8% year-over-year, from -$166.00M to -$12.00M.
- What is the long-term trend for Johnson & Johnson's innovative medicine — other (income) expense, net?
- Over 3 years (2022 to 2025), Johnson & Johnson's innovative medicine — other (income) expense, net has grown at a -21.9% compound annual growth rate (CAGR), from $1.49B to -$713.00M.
- What does innovative medicine — other (income) expense, net mean?
- Miscellaneous income or expenses for the Innovative Medicine segment that are not part of core operations.